Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
OBJECTIVE
To evaluate the association between syndecan-1 (CD138) expression and prostate cancer.


METHODS
We evaluated syndecan-1 expression using a recently constructed tissue microarray of prostatic samples taken from 243 patients, corresponding to 1400 cores, with 69.8%, 5.6%, 17.6% and 7% of the cores representing localized prostate cancer, high-grade prostatic intraepithelial neoplasia, benign prostate tissue and hormone refractory/metastatic disease, respectively.


RESULTS
Metastatic cases had the highest frequency and membranous staining intensity for syndecan-1 overexpression, followed by hormone refractory and localized disease (83.3% vs 34.8% and 25.7%, respectively). There was no significant difference in the frequency of membranous syndecan-1 expression between localized prostate cancer and benign glands (25.7% vs 24.7% of cases, respectively). However, benign glands showed significantly higher intensity staining than localized prostate cancer. We found no significant association between syndecan-1 expression and any of the following: Gleason score, pathological stage, surgical margin status and biochemical recurrence.


CONCLUSIONS
The current available evidence, from the present and previous studies, show that syndecan-1 is not an independent predictor of recurrence or tumour-specific survival, diminishing its significance as a clinical marker.
Brimo
Fadi
F
Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada.
Vollmer
Robin T
RT
Friszt
Matthew
M
Corcos
Jacques
J
Bismar
Tarek A
TA
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011379:Prognosis; D019048:Prostatic Intraepithelial Neoplasia / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D053668:Syndecan-1 / Q000378:metabolism*; D046888:Tissue Array Analysis
D014408:Biomarkers, Tumor; D053668:Syndecan-1